The World Health Organization recommended prioritizing three experimental treatments for the Bundibugyo strain of Ebola, including Mapp Biopharmaceutical's MBP134, Regeneron's maftivimab and Gilead Sciences' antiviral remdesivir.
The WHO said on Thursday the drugs and other candidate vaccines should be evaluated in clinical trials to generate data on their use. The agency and outside experts have been working to identify several candidates.
The move comes as an outbreak continues in the Democratic Republic of the Congo, with cases also reported in Uganda.
Also Read
Tanzania seeks investors for massive redevelopment drive move
